Status:

WITHDRAWN

Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL

Lead Sponsor:

Mayo Clinic

Conditions:

Cadasil

Migraine

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Researchers are trying to find out more about the side effects of fremanezumab when treating patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (C...

Detailed Description

Subjects will receive 4 to 20 weeks of placebo injections followed by 12 weeks of monthly administered fremanezumab by subcutaneous injection (225 mg split four weeks apart for 12 weeks). Following co...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age 18 to 70 years old
  • English speaking
  • Diagnosis of CADASIL confirmed by presence of a pathogenic NOTCH3 gene mutation
  • Diagnosis of migraine for at least 12 months and diagnosis of chronic migraine for at least 28 days according to the International Classification of Headache Disorders
  • MIDAS score of \>10 points
  • Ability to provide written informed consent
  • Exclusion Criteria
  • History of ischemic stroke within 4 weeks of screening assessment
  • Screening blood pressure \>150 mm Hg
  • Use of onabotulinum toxin A 4 months prior to trial or other injectable/stimulatory/magnetic method of headache control
  • Use of opiates or barbiturates 4 days prior to trial
  • Patients with competing intracerebral pathology (e.g. history of intracerebral hemorrhage, multiple sclerosis)
  • NYHA Class III or IV congestive heart failure
  • History of myocardial infarction
  • History of coronary bypass surgery or coronary stenting
  • Pregnancy or breastfeeding
  • Contraindication to undergoing brain MRI per standard clinical practice guidelines
  • Vulnerable populations, including incarcerated inmates, dementia, and inability to provide consent

Exclusion

    Key Trial Info

    Start Date :

    December 1 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2024

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT04334408

    Start Date

    December 1 2021

    End Date

    December 1 2024

    Last Update

    February 28 2022

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | DecenTrialz